A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

Trial Profile

A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Lopixibat chloride (Primary)
  • Indications Alagille syndrome; Cholestasis
  • Focus Adverse reactions
  • Acronyms IMAGINE-II
  • Sponsors Lumena Pharmaceuticals; Shire
  • Most Recent Events

    • 19 Apr 2017 Planned End Date changed from 1 Oct 2017 to 19 Oct 2018.
    • 19 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 19 Oct 2018.
    • 13 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top